Cancers, Vol. 12, Pages 896: Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch ® and ISET

Cancers, Vol. 12, Pages 896: Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET Cancers doi: 10.3390/cancers12040896 Authors: Tamminga Andree Hiltermann Jayat Schuuring van den Bos Spierings Lansdorp Timens Terstappen Groen Circulating tumor cells (CTCs) detected by CellSearch are prognostic in non-small-cell lung cancer (NSCLC), but rarely found. CTCs can be extracted from the blood together with mononuclear cell populations by diagnostic leukapheresis (DLA), therefore concentrating them. However, CellSearch can only process limited DLA volumes (≈2 mL). Therefore, we established a protocol to enumerate CTCs in DLA products with Isolation by SizE of Tumor cells (ISET), and compared CTC counts between CellSearch® and ISET. DLA was performed in NSCLC patients who started a new therapy. With an adapted protocol, ISET could process 10 mL of DLA. CellSearch detected CTCs in a volume equaling 2 × 108 leukocytes (mean 2 mL). CTC counts per mL were compared. Furthermore, the live cell protocol of ISET was tested in eight patients. ISET successfully processed all DLA products—16 with the fixed cell protocol and 8 with the live cell protocol. In total, 10–20 mL of DLA was processed. ISET detected CTCs in 88% (14/16), compared to 69% (11/16, p < 0.05) with CellSearch. ISET also detected higher nu...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research

Related Links:

CONCLUSION: This study revealed that EGFR mutation status and BM might be predictive or prognostic factors for PFS. PMID: 32464632 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
CONCLUSION: MiR-210 secreted by CAFs-exo could promote EMT by targeting UPF1 and activating PTEN/PI3K/AKT pathway, thereby promoting NSCLC migration and invasion. PMID: 32446904 [PubMed - as supplied by publisher]
Source: Cellular Signalling - Category: Cytology Authors: Tags: Cell Signal Source Type: research
In conclusion, our data highlight the role of the CXCR4-OE/MIF/IL-6 axis in epithelial mesenchymal crosstalk and NSCLC progression. PMID: 32428553 [PubMed - as supplied by publisher]
Source: Cellular Signalling - Category: Cytology Authors: Tags: Cell Signal Source Type: research
Inhibition of Wnt/β-catenin pathway reverses multi-drug resistance and EMT in Oct4+/Nanog+ NSCLC cells. Biomed Pharmacother. 2020 May 16;127:110225 Authors: Liu L, Zhu H, Liao Y, Wu W, Liu L, Liu L, Wu Y, Sun F, Lin HW Abstract Cancer drug resistance and epithelial-mesenchymal transition (EMT), a critical process of cancer invasion and metastasis, have recently been associated with the existence of cancer stem cells (CSCs). However, there are no appropriate CSC-markers of non-small cell lung cancer (NSCLC)-associated drug resistance and EMT. It is unknown if and how the drug-resistant and EMT phe...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
MET, a hepatocyte growth factor receptor, is expressed throughout epithelial and endothelial cells. Functional characterization shows that activation of c-Met orchestrates signaling pathways culminating in cell cycle regulations, facilitating activities such as cell proliferation, invasion, survival, angiogenesis, and motility. MET amplification and MET exon 14 skipping have been observed in various cancers, and was demonstrated to be not only an actionable mutation to crizotinib, but also one of the resistance mechanisms to EGFR tyrosine kinase inhibitors [1,2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: MiR-200c-3p plays a role in sensitivity to EGFR TKIs via modulating EMT process. PMID: 32417760 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers : Section A of Disease Markers - Category: Cancer & Oncology Authors: Tags: Cancer Biomark Source Type: research
Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced,EGFR‐mutated non‐small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority of patients, severe and even life‐threatening side effects have been reported. TKI‐induced interstitial lung disease (ILD) has been reporte d for single cases in modest severity, predominantly in EGFR‐TKI pretreated patients. Here, we report a case of successful stabilization of a life‐threatening ILD in a de novo T7...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Thymic epithelial cell tumors (TETs) form a group of rare neoplasms arising in the anterior mediastinum [1]. The histological subtypes according to the World Health Organization (WHO) classification vary from the low-grade type A thymomas to the high-grade type B3 thymomas and thymic carcinomas (TCs) [2]. Therapy with immune checkpoint inhibitors has recently been approved for non-small cell lung cancer (NSCLC) and has shown promising results, with clinical efficacy predictable on the basis of the extent of programmed death-ligand 1 (PD-L1) expression as determined by immunohistochemistry [3].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract To identify potential therapeutic targets in non-small cell lung cancer NSCLC, we conducted a bioinformatics analysis of circRNAs differentially expressed between NSCLC tissues and adjacent normal tissues. Cell proliferation and apoptosis was assessed using CCK-8 and flow cytometry, respectively. A connection between hsa_circ_0018818 and miR-767-3p was confirmed in dual luciferase reporter assays. Gene and protein expression in NSCLC cells were measured using quantitative PCR and Western-blotting, respectively. And a xenograft tumor model was established to assess the function of hsa_circ_0018818 in NSCLC...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells. Oncol Rep. 2020 Mar 10;: Authors: Li F, Cui H, Jin X, Gong X, Wang W, Wang J Abstract The epidermal growth factor receptor‑tyrosine kinase inhibitor (EGFR‑TKI), gefitinib, is used widely to treat non‑small cell lung cancer (NSCLC) with EGFR‑activating mutations. Unfortunately, the acquired drug resistance promoted by epithelial‑mesenchymal transition (EMT) markedly limits the clinical effects and remains a major barrier to a cure. Our previous isobaric tags for relative an...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Lung Cancer | Non-Small Cell Lung Cancer